

SWEDISH BIOTECH FLUICELL AB SHINES IN PRIVATE PLACEMENT ROUND REACHING CLOSE TO 300% OVERSUBSCRIPTION RATE

Fluicell AB is pleased to announce the closing of 8MSEK private placement round in April 2017 that reached an oversubscription rate of 300%.

“We are honored by the great interest shown for Fluicells growth potential during the private placement and we thank InWest Corporate Finance AB and Roger Lundin for their assistance during the process” says Victoire Viannay, CEO of Fluicell AB.

The company prepares for a stock market listing later this year, and the proceeds from this investment will be used for key people recruitments as well as to expand and complement current product offerings with a continued focus on transformative single-cell biology, and bioprinting technologies.

For further information, please visit us at fluicell.com or contact:

Victoire Viannay, CEO

Tel: +46 725 65 42 05

E-mail: victoire@fluicell.com

About Fluicell

Fluicell is a Swedish high-tech company that brings inspiration and innovation to life science researchers around the globe. Fluicell provides innovative tools with outstanding performance, redefining approaches within cell biology, bioprinting, and secondary drug screening, and discovery. Fluicell strives for technology solutions which are environmentally friendly, sustainable, and that ultimately reduces cost, spares resources, and minimizes the use of animals for research. Fluicells main target sectors include universities, the pharmaceutical industry, and national health laboratories.